Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-1/A IPO registration
- 1.1 Form of Underwriting Agreement
- 2.2 Side Letter to Contribution Agreement
- 3.4 Form of Certificate of Designation
- 3.5 Form of Certificate of Designation
- 4.4 Third Amended and Restated Investor Promissory Note
- 4.5 Side Letter to Second Amended and Restated Investor Promissory Note
- 10.2 Amended and Restated Employment Agreement (Christian Kopfli)
- 10.6 Securities Purchase Agreement (September Bridge Financing)
- 10.7 Security Agreement (September Bridge Financing)
- 10.8 Subordination and Intercreditor Agreement (September Bridge Financing)
- 10.9 Form of Securities Purchase Agreement (Series B Preferred Stock)
- 10.10 Form of Registration Rights Agreement
- 10.11 Form of Amendment to Chromocell Therapeutics Corporation 2023 Equity Incentive Plan
- 23.1 Consent of Marcum LLP
CHRO similar filings
Filing view
External links
Exhibit 10.12
FIRST AMENDMENT TO THE CHROMOCELL THERAPEUTICS CORPORATION
2023 EQUITY INCENTIVE PLAN
______________________________________________
As adopted by resolution of the
Board of Directors effective as of [September __, 2023]
______________________________________________
1. Section 3 of the Chromocell Therapeutics Corporation 2023 Equity Incentive Plan (the “2023 Plan”) is amended by deleting the number “3,000,000” and inserting therefor “4,000,000.”
2. Except as hereinabove amended, the provisions of the 2023 Plan shall remain in full force and effect.
1 |